In correlative studies of phase II trials in sarcoma, testing the impact of PD1/PD-L1 inhibition, and in recent reviews, no relevant correlation implying WNT signaling in poor responders has been reported [209,210,211,212,213]. The gene discussed is CD274; the disease is sarcoma.